• (0:30) – Everything You Need To Know About The Marijuana Industry
• (4:30) – Stocks To Keep On Your Radar
• (10:30) – Will It Ever Be Federaly Legal?
• (15:15) – A Different Play On Cannabis: Beauty Products & REITs
• (23:00) – What Should Investors Be Keeping Their Eye On?
• (27:15) – Episode Roundup: CGC, ACB, HEXO, GWPH, IIPR, ZYNE

Welcome to Episode #230 of the Zacks Market Edge Podcast.

Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.

This week, Tracey’s joined by Stock Strategist David Borun, the editor of Zacks Marijuana Innovators portfolio, to discuss what is going on with the cannabis industry.

Did the coronavirus pandemic help, or hurt, the cannabis industry?

In many states, cannabis was considered an essential business so most dispensaries remained open. But that doesn’t mean there wasn’t disruptions to some of the businesses.

Is it Time to Buy Cannabis Stocks?

Many of the stocks plunged when the stock market plunged in February and March on coronavirus fears.

Has that created a buying opportunity in some of the shares?

Growers and Pharmaceuticals

Many investors have focused on the Canadian cannabis growers the last few years. But the pandemic has caused a shake-up among the companies with several doing layoffs and cutting expenses.

Some intriguing places to look for deals are in pharmaceuticals.

1.       Canopy Growth CGC shares have fallen 46% over the last 2 years and are still down 16% year-to-date. It’s making beverages and chocolates. Is it time to buy?

2.       Aurora Cannabis ACB recently announced more lay offs and is closing operations at 5 smaller facilities. It’s also taking a $140 inventory charge. Shares are down 45% year-to-date. Is the worst priced in?

3.       Hexo Corporation HEXO is a Canadian grower trading under $1. Many investors love that but that increases the risk. It has a $314 million market cap, however, and is a play on beverages due to a joint venture with Molson Coors.

4.       GW Pharmaceuticals GWPH has the first FDA approved cannabis drug which is approved for some rare forms of epilepsy. Sales are expected to rise 82% this year and the company is forecast to see positive earnings as soon as 2021. Shares are up 19% year-to-date. Is it too late to get in?

5.       Zynerba Pharmaceuticals ZYNE is a micro-cap biotech that has no revenue but has cannabinoid therapeutics addressing autism disorders. Shares are up just 3% year-to-date. Is this a buying opportunity?

What else should you know about the marijuana stocks in 2020?

Listen to this week’s podcast to find out.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research